Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Stemline Therapeutics Raises US$0.74 Million In Venture Financing 11
Partnerships 12
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 12
Licensing Agreements 13
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 13
Stemline Therapeutics Enters into Licensing Agreement with CanBas 14
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 15
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For EphA2 16
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For SL-701 17
Equity Offering 18
Stemline Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 18
Stemline Therapeutics Raises USD59.6 Million in Public Offering of Shares 19
Stemline Therapeutics Prices Public Offering of Shares for USD45 Million 21
Stemline Therapeutics Raises USD60 Million in Public Offering of Shares 23
Stemline Therapeutics Announces Full Exercise Of Underwriter’s Option For Public Offering Of Shares For US$69 Million 25
Stemline Therapeutics Completes IPO For US$38.15 Million 27
Stemline Therapeutics Inc – Key Competitors 29
Stemline Therapeutics Inc – Key Employees 30
Stemline Therapeutics Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 09, 2018: Stemline Therapeutics reports second quarter 2018 financial results 32
May 09, 2018: Stemline Therapeutics Reports First Quarter 2018 Financial Results 34
Mar 16, 2018: Stemline Therapeutics Announces Fourth Quarter 2017 Financial Results 35
Nov 09, 2017: Stemline Therapeutics Reports Third Quarter 2017 Financial Results 37
Aug 08, 2017: Stemline Therapeutics Reports Second Quarter 2017 Financial Results 38
May 10, 2017: Stemline Therapeutics Reports First Quarter 2017 Financial Results 39
Mar 16, 2017: Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results 40
Corporate Communications 41
Apr 16, 2018: Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline 41
Product News 42
12/13/2017: Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented 42
08/13/2018: Stemline Therapeutics announces that FDA accepts ELZONRIS Biologics License Application and grants Priority Review 44
06/18/2018: Stemline Therapeutics Announces Positive Clinical Data from ELZONRIS (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress 45
Product Approvals 47
Jun 25, 2018: Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS (tagraxofusp; SL-401) for the Treatment of BPDCN 47
Apr 05, 2018: Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401 48
Clinical Trials 49
Jun 15, 2018: Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress 49
Jun 14, 2018: Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress 50
May 18, 2018: Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress 51
Dec 08, 2017: Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting 52
Nov 01, 2017: Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting 53
Oct 31, 2017: Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint 54
Jun 23, 2017: Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA 55
May 18, 2017: Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association Meeting 56
Mar 23, 2017: Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN 57
Mar 16, 2017: Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results 58
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-401 59
Feb 02, 2017: Stemline Therapeutics Provides Update on Pivotal BPDCN Trial 60
Jan 05, 2017: Stemline Therapeutics Announces Positive FDA Meeting and Agreement on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stemline Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Stemline Therapeutics Raises US$0.74 Million In Venture Financing 11
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 12
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 13
Stemline Therapeutics Enters into Licensing Agreement with CanBas 14
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 15
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For EphA2 16
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For SL-701 17
Stemline Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 18
Stemline Therapeutics Raises USD59.6 Million in Public Offering of Shares 19
Stemline Therapeutics Prices Public Offering of Shares for USD45 Million 21
Stemline Therapeutics Raises USD60 Million in Public Offering of Shares 23
Stemline Therapeutics Announces Full Exercise Of Underwriter's Option For Public Offering Of Shares For US$69 Million 25
Stemline Therapeutics Completes IPO For US$38.15 Million 27
Stemline Therapeutics Inc, Key Competitors 29
Stemline Therapeutics Inc, Key Employees 30
List of Figures
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer